Placebo Eprosartan mesylate — Competitive Intelligence Brief

Placebo Eprosartan mesylate (Placebo Eprosartan mesylate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor antagonist. Area: Cardiovascular.

phase 3 Angiotensin II receptor antagonist AT1 receptor Cardiovascular Small molecule

Target snapshot

Placebo Eprosartan mesylate (Placebo Eprosartan mesylate) — Abbott. Eprosartan mesylate is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, to lower blood pressure.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo Eprosartan mesylate TARGET	Placebo Eprosartan mesylate	Abbott	phase 3	Angiotensin II receptor antagonist	AT1 receptor
Edarbi	AZILSARTAN MEDOXOMIL	Arbor Pharms Ireland	marketed	Angiotensin 2 Receptor Blocker	AT1 receptor	2011-01-01
Cozaar	losartan	Merck & Co.	marketed	ARB (Angiotensin II receptor blocker)	AT1 receptor	1995-04-14
placebo/valsartan	placebo/valsartan	Medical University of Silesia	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
Candesartan cilexetil/Amlodipine besylate	Candesartan cilexetil/Amlodipine besylate	HK inno.N Corporation	marketed	Angiotensin II receptor blocker / Calcium channel blocker combination	AT1 receptor (angiotensin II type 1 receptor) / L-type voltage-gated calcium channel
olmesartan medoxomil+probenecid	olmesartan medoxomil+probenecid	Central South University	marketed	Angiotensin II receptor blocker + uricosuric agent	AT1 receptor (angiotensin II type 1 receptor); uric acid transporter (URAT1)
Valsartan+/- Hydrochlorothiazide	Valsartan+/- Hydrochlorothiazide	Novartis	marketed	Angiotensin II receptor blocker (ARB); combination with thiazide diuretic when applicable	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter (thiazide component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2028-03-26 — Edarbi · 9066936 · US
• 2030-02-04 — Edarbi · 9169238 · US
• 2031-07-01 — Edarbi · 9387249 · US

Sponsor landscape (Angiotensin II receptor antagonist class)

1. Abbott · 1 drug in this class
2. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 drug in this class
3. Ain Shams University · 1 drug in this class
4. Boryung Pharmaceutical Co., Ltd · 1 drug in this class
5. Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · 1 drug in this class
6. EMS · 1 drug in this class
7. Kaohsiung Medical University Chung-Ho Memorial Hospital · 1 drug in this class
8. Merck Sharp & Dohme LLC · 1 drug in this class
9. St. Joseph's Hospital and Medical Center, Phoenix · 1 drug in this class
10. Tanabe Pharma Corporation · 1 drug in this class